Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran, Vice President of Scientific Affairs at Enzo Clinical Labs

Enzo Biochem, Inc. (NYSE:ENZ) today announced the appointment of Mohan Chellani, Ph.D., formerly a senior manager with Quest Diagnostics, as Vice President of Scientific Affairs at its Enzo Clinical Labs subsidiary. He will oversee all aspects of the Labs’ Molecular Diagnostic’s strategy and implementation, including serving as a key interface with Enzo Life Sciences, another Enzo subsidiary.

Enzo Biochem is a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services.

"Dr. Chellani adds outstanding experience that will greatly benefit us,” said Dr. Kevin Krenitsky, President, Enzo Clinical Labs. "We are on target at the Labs to not only capitalize on our progress in quality improvement, but also to further our growth strategy to broaden our capabilities in molecular diagnostics and other new dynamic, esoteric tests in line with today’s advances in medicine. Dr. Chellani is an important addition to our team, and we are pleased to have him join us.”

Dr. Chellani, with over 15 years experience in the clinical laboratory business, most recently was Head of Science and Innovation Portfolio Development at Quest Diagnostics. Among his responsibilities were growing Quest’s esoteric testing business, introducing assays and regionalized tests, and directing product development collaborations with academic and industry partners. Previously, Dr. Chellani served as a Senior Scientist in molecular immunology at Abbott Laboratories, head of Molecular Biology at PerSeptive Diagnostics, director of business development for biocalorimetric assays at MicroCal Inc., and Program Director, Biomics, at Perkin Elmer Life Sciences.

About Enzo

Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo’s Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 40,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo’s Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company’s technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.